## Clinical Context This child presents with clinical vitamin A deficiency (night blindness, Bitot's spots, xerophthalmia) with biochemical confirmation (serum retinol <20 µg/dL). Xerophthalmia is a medical emergency that can rapidly progress to corneal scarring and permanent blindness. ## Pathophysiology of Vitamin A Deficiency **Key Point:** Vitamin A (retinol) is essential for: - Synthesis of rhodopsin (visual pigment) — deficiency causes night blindness (earliest sign) - Maintenance of epithelial cell differentiation — deficiency causes xerophthalmia, Bitot's spots (foamy appearance of conjunctiva) - Immune function — deficiency increases infection susceptibility ## WHO/UNICEF Protocol for Vitamin A Deficiency **High-Yield:** The standard therapeutic regimen for xerophthalmia in children is: 1. **Day 1:** 200,000 IU orally 2. **Day 2:** 200,000 IU orally (repeat) 3. **Day 14 (2 weeks later):** 200,000 IU orally (final dose) This three-dose schedule is evidence-based and recommended by WHO for children with clinical signs of deficiency [cite:Park 26e Ch 8]. ## Why This Dosing? - **Immediate repletion:** High-dose oral vitamin A rapidly restores retinol stores - **Prevents progression:** Halts xerophthalmia progression to corneal ulceration/scarring - **Systemic benefits:** Restores immune function, reduces mortality in deficient children by ~12% - **Practical:** Oral route is feasible in community settings; IM route reserved for malabsorption or unconscious patients ## Mnemonic: "VAD Emergency — 2-2-14" **Vitamin A Deficiency → 200,000 IU on Day 1, Day 2, and Day 14** **Clinical Pearl:** Bitot's spots (foamy, triangular conjunctival patches) are pathognomonic for vitamin A deficiency and indicate corneal involvement is imminent — treatment cannot be delayed.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.